Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
This manuscript describes a step-by-step protocol for the generation and quantification of diverse reprogrammed cardiac subtypes using a retrovirus-mediated delivery of Gata4, Hand2, Mef2c, and Tbx5.
Direct reprogramming of one cell type into another has recently emerged as a powerful paradigm for regenerative medicine, disease modeling, and lineage specification. In particular, the conversion of fibroblasts into induced cardiomyocyte-like myocytes (iCLMs) by Gata4, Hand2, Mef2c, and Tbx5 (GHMT) represents an important avenue for generating de novo cardiac myocytes in vitro and in vivo. Recent evidence suggests that GHMT generates a greater diversity of cardiac subtypes than previously appreciated, thus underscoring the need for a systematic approach to conducting additional studies. Before direct reprogramming can be used as a therapeutic strategy, however, the mechanistic underpinnings of lineage conversion must be understood in detail to generate specific cardiac subtypes. Here we present a detailed protocol for generating iCLMs by GHMT-mediated reprogramming of mouse embryonic fibroblasts (MEFs).
We outline methods for MEF isolation, retroviral production, and MEF infection to accomplish efficient reprogramming. To determine the subtype identity of reprogrammed cells, we detail a step-by-step approach for performing immunocytochemistry on iCLMs using a defined set of compatible antibodies. Methods for confocal microscopy, identification, and quantification of iCLMs and individual atrial (iAM), ventricular (iVM), and pacemaker (iPM) subtypes are also presented. Finally, we discuss representative results of prototypical direct reprogramming experiments and highlight important technical aspects of our protocol to ensure efficient lineage conversion. Taken together, our optimized protocol should provide a stepwise approach for investigators to conduct meaningful cardiac reprogramming experiments that require identification of individual CM subtypes.
The heart is the first functional organ to develop in the embryo1,2. In conjunction with the circulatory system, it supplies oxygen, nutrients, and a waste disposal mechanism during development. Three weeks after fertilization, the human heart beats for the first time and its proper regulation is maintained by cardiomyocytes (CMs). The irreversible loss of these specialized cells is therefore the fundamental issue underlying progressive heart failure. While some organisms such as the zebrafish and Xenopus have the potential for cardiac regeneration, the adult mammalian heart is more limited3,5,6. Thus, given the critical function of the heart, it is not astonishing that heart disease is the leading cause of death in the world, accounting for 600,000 deaths in the United States alone7. Therefore, cell-based therapies to efficiently repair or replace the injured myocardium are of great clinical interest.
The seminal study of Yamanaka and colleagues8 showed that forced expression of four transcription factors is sufficient to convert fully differentiated fibroblast cells to pluripotent stem cells. However, the tumorigenic capacity of all pluripotent stem cell strategies has been a critical concern in their use for therapeutic purposes. This motivated the scientific field to search for alternative methods to transdifferentiate cells while avoiding a pluripotent stage. Recently, several groups have shown the feasibility of this strategy by displaying direct conversion of mouse fibroblasts to induced cardiomyocyte-like cells (iCLMs) with the ectopic expression of the transcription factors Gata4, Mef2c, Tbx5, and later on, Hand2 (GMT and GHMT, respectively)9,10. Furthermore, the same strategy can be performed in vivo and in human-derived tissues9,11,12. Recent studies have highlighted additional factors or signaling pathways that can be modulated to further improve cardiac reprogramming efficiency13,14,15. Taken together, these studies demonstrate the potential of directed transdifferentiation for regenerative therapies. However, the low efficiency of CM reprogramming, the unknown molecular mechanisms, inconsistent reproducibility due to methodological differences16, and the heterogeneous nature of iCLMs remain unaddressed.
In order to directly evaluate iCLM heterogeneity, we designed a discrete and robust single-cell assay for the identification of sarcomere development and cardiac lineage specification-two necessary characteristics of functional cardiomyocytes. There are at least three major types of CM in the heart as defined by their location and unique electrical properties: atrial (AM), ventricular (VM) and pacemaker (PM)17,18,19,20. In an orchestrated combination, they allow the proper pumping of blood. During heart injury, one or all subtypes might be affected, and the type of cell therapy would need to be addressed on a case-by-case basis. Currently, most strategies focus on the overall generation of cardiomyocytes, while little work is being done to study the molecular mechanisms that regulates subtype specification.
The following study details how to properly quantify well-organized sarcomeres and identify a diverse set of cardiomyocyte subtypes. Using a pacemaker (PM)-specific reporter mouse, we are able to apply an immunocytochemical approach to distinguish induced atrial-like myocytes (iAM), induced ventricular-like myocytes (iVM), and induced PM-like myocytes (iPMs)21. Based on our observations, only cells that exhibit sarcomere organization are capable of spontaneous beating. This unique reprogramming platform allows for assessing the role of certain parameters in sarcomere organization, subtype specification, and efficiency of CM reprogramming at single-cell resolution.
All experimental procedures involving animal practices were approved by the Institutional Animal Care and Use Committee at UT Southwestern Medical Center.
1. Isolation of Hcn4-GFP E12.5 Mouse Embryonic Fibroblast (MEFs)
2. Retrovirus Production and Reprogramming
Caution: The following protocol requires production and handling of infectious retroviruses. Perform the following steps in a Biosafety Level 2 cabinet under BSL-2 guidelines and sterile technique. Use 10% bleach to dispose of all materials exposed to retroviruses.
3. Immunostaining of Reprogrammed MEFs
4. Identification of Cardiac Subtypes Using Confocal Microscopy
NOTE: For imaging, a confocal microscope equipped with at least 2 fluorescent detectors capable of spectral detection at 405, 488, 555, and 639 nm wavelengths is necessary in order to identify iPMs, iAMs, and iVMs. Image cells using a Plan-Apochromat 20X/0.75 objective or better. Using the manufacturer's image analysis software, scanning zoom images can achieve 40X-oil immersion quality images.
5. Quantification
NOTE: In order to assess the actual number of potentially reprogrammed MEFs, 2 wells of a 24-well plate are seeded in parallel to the experimental wells and are harvested one day after plating. The total number of cells plated is then determined by averaging the two wells. This becomes the actual total cells plated (aTotal).
Taking advantage of the PM-specific reporter mouse, we developed a multiplex immunostaining strategy to identify diverse endogenous myocytes as depicted in Figure 1. Following the reprogramming steps shown in Figure 2, induction of subtype-specific CMs can be detected as early as day 421, albeit at a low-rate. By day 14, the experiment can be stopped and assessed for sarcomere organization (Figure 3) and subtype-sp...
The present study provides a direct-reprogramming strategy for conversion of MEFs into a diverse set of cardiac subtypes via retrovirus-mediated expression of the cardiac transcription factors Gata4, Mef2c, Tbx5, and Hand2 (GHMT). Using a multiplex immunostaining approach in combination with a PM-specific reporter mouse, we are able to identify iAM, iVMs, and iPMs at single cell resolution. Such an assay allows for an experimental in vitro system capable of isolating the contributions of individual transcription...
The authors have nothing to disclose.
A.F.-P. was supported by the National Science Foundation Graduate Research Fellowship under Grant No.2015165336. N.V.M was supported by grants from the NIH (HL094699), Burroughs Wellcome Fund (1009838), and the March of Dimes (#5-FY14-203). We acknowledge Young-Jae Nam, Christina Lubczyk, and Minoti Bhakta for their important contributions to protocol development and data analysis. We also thank John Shelton for valuable technical input and members of the Munshi lab for scientific discussion.
Name | Company | Catalog Number | Comments |
DMEM | Sigma | D5796 | Component of iCLM media, Plat-E media, fibroblast, and Transfection media |
Medium 199 | Thermo Fisher Scientific | 11150059 | Component of iCLM media |
Fetal bovine serrum (FBS) | Sigma | F2442 | Component of iCLM media, Plat-E media, fibroblast, and Transfection media |
Insulin-Transferrin-Selenium G | Thermo Fisher Scientific | 41400-045 | Component of iCLM media |
MEM vitamin solution | Thermo Fisher Scientific | 11120-052 | Component of iCLM media |
MEM amino acids | Thermo Fisher Scientific | 1601149 | Component of iCLM media |
Non-Essential amino acids | Thermo Fisher Scientific | 11140-050 | Component of iCLM media |
Antibiotic-Antimycotics | Thermo Fisher Scientific | 15240062 | Component of iCLM media |
B-27 supplement | Thermo Fisher Scientific | 17504044 | Component of iCLM media |
Heat-Inactivated Horse Serum | Thermo Fisher Scientific | 26050-088 | Component of iCLM media |
NaPyruvate | Thermo Fisher Scientific | 11360-70 | Component of iCLM media |
Penicillin/Streptomycin | Thermo Fisher Scientific | 1514022 | Component of Plat-E media and fibroblast media |
Puromycin | Thermo Fisher Scientific | A11139-03 | Component of Plat-E media |
Blasticidin | Gemini Bio-Products | 400-128P | Component of Plat-E media |
Glutamax | Thermo Fisher Scientific | 35050-061 | Component of Fibroblast media |
Confocal laser scanning LSM700 | Zeiss | For confocal analysis | |
FuGENE 6 transfection Reagent | Promega | E2692 | Transfection reagent |
Opti-MEM Reduced Serum Medium | Thermo Fisher Scientific | 31985-070 | Transfection reagent |
Polybrene | Millipore | TR-1003-G | Induction reagent. Use at a final concentration of 8 μM/mL |
Platinium-E (PE) Retroviral Packagin Cell Line, Ecotropic | CellBiolabs | RV-101 | Retroviral pacaking cell line |
Trypsin 0.25% EDTA | Thermo Fisher Scientific | For MEFs and Plat-E dissociation | |
Mouse anti α-Actinin (Clone EA-53) | Sigma | A7811 | Antibody for confocal analysis. Use at 1:200 |
Chicken anti-GFP IgY | Thermo Fisher Scientific | A10262 | Antibody for confocal analysis. Use at 1:200 |
Rabbit Pab anti-NPPA | Abgent | AP8534A | Antibody for confocal analysis. Use at 1:400 |
Rabbit Pab anti Myl2 IgG | ProteinTech | 10906-1-AP | Antibody for confocal analysis. Use at 1:200 |
Vectashield solution with DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) | Vector Labs | H-1500 | Dye for confocal analysis |
Superfrost Plus Microscope slides | Thermo Fisher Scientific | 12-550-15 | 25 x 75 x 1.0 mm |
BioCoat Fibronectin 12 mm coverslips | NeuVitro Corp | GG-12-1.5 | Coverslips for confocal analysis |
100 μm cell strainer | Thermo Fisher Scientific | 08-771-19 | |
0.45 μm Syringes filters SFCA 25MM | Thermo Fisher Scientific | 09-740-106 | For virus filtration |
6 mL Syringes | Covidien | 8881516937 | For virus filtration |
Goat anti-Chicken IgY (H&L) A488 | Abcam | AB150169 | Secondary antibody for confocal analysis. Use at 1:400 |
Donkey anti-rabbit A647 IgG(H+L) | Thermo Fisher Scientific | A31573 | Secondary antibody for confocal analysis. Use at 1:400 |
Goat anti-mouse IgG(H+L) A555 | Thermo Fisher Scientific | A21422 | Secondary antibody for confocal analysis. Use at 1:400 |
Triton X-100 | Sigma | 93443-100ml | For cell permeabilization |
Dulbecco's PBS without CaCl2 and MgCl2 (D-PBS) | Sigma | D8537 | |
Power Block 10x Universal Blocking reagent | Thermo Fisher Scientific | NC9495720 | Dilute to 1x in H2O |
16% Paraformaldehyde aqueous solution (PFA) | Electro Microscopy Sciences | 15710 | Use at 4% diluted in dH2O |
6 cm plates | Olympus | 25-260 | |
6-well plates | Genesee Scientific | 25-105 | |
24-well plates | Genesee Scientific | 25-107 | |
10 cm Tissue culture dishes | Corning | 4239 | |
15 cm Tissue culture dishes | Thermo Fisher Scientific | 5442 | |
15 mL Conical tubes | Corning | 4308 | |
50 mL Conical tubes | Corning | 4249 | |
0.4% Trypan blue solution | Sigma | T8154 | For viability |
Ethyl Alcohol 200 proof | Thermo Fisher Scientific | 7005 | |
Bleach | Thermo Fisher Scientific | 6009 |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone